Prothera Biologics

ProThera Biologics has been dedicated from its founding to the development of Inter-alpha Inhibitor Proteins for the management of life-threatening inflammatory conditions in addition to a fast, on-the-spot diagnostic test for assessing IAIP levels as a biomarker for patient progression to severe outcomes. ProThera has exhibited the promise of IAIP therapy in numerous preclinical scenarios and the utilization of IAIP as a biomarker in clinical specimens.